Private equity firm Advent-backed Bharat Serums and Vaccines (BSV) on Tuesday said it has acquired Tidilan (isoxsuprine hydrochloride), a leading brand in women’s health from Bengaluru-based Jagdale Industries.
BSV didn’t disclose the financial details of the acquisition or the annual sales of the Tidilan.
Tidilan is currently available in tablet and injectable dosage forms. BSV has some of the leading women’s health brands such as Rhoclone, Hucog, AntiD, among others.
Tidilan is used for relaxing uterine muscles to prevent premature labour, among expecting mothers. It belongs to a class of medication called ‘vasodilator’ and is also used to treat and prevent Raynaud’s phenomenon, cerebral vascular insufficiency (arteriosclerosis), and other conditions involving poor blood flow in the blood vessels.
Backed by Advent BSV is looking to strengthen its women’s health portfolio. The company last month agreed to TTK Healthcare’s pharma business for Rs 805 crore, which gives it access to the latter’s key women health brands.
“As a focused women’s health company, we are committed to acquiring brands that complement our current women’s portfolio,” said Sanjiv Navangul, managing director & CEO of BSV.
“We are delighted with the addition of Tidilan to BSV’s Women’s Healthcare portfolio. This will be an important milestone towards our goal of being the top three women’s health players in India,” Navangul added.
